Ocular Therapeutix (OCUL)
(Delayed Data from NSDQ)
$8.03 USD
-0.34 (-4.06%)
Updated Aug 8, 2024 04:00 PM ET
After-Market: $8.04 +0.01 (0.12%) 7:52 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Income Statements
Fiscal Year end for Ocular Therapeutix, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 58 | 51 | 44 | 17 | 4 |
Cost Of Goods | 5 | 5 | 4 | 2 | 2 |
Gross Profit | 53 | 47 | 39 | 15 | 2 |
Selling & Adminstrative & Depr. & Amort Expenses | 136 | 126 | 117 | 78 | 88 |
Income After Depreciation & Amortization | -82 | -79 | -78 | -63 | -86 |
Non-Operating Income | 13 | 15 | 78 | -86 | 6 |
Interest Expense | 11 | 7 | 7 | 7 | 6 |
Pretax Income | -81 | -71 | -7 | -156 | -86 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -81 | -71 | -7 | -156 | -86 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -81 | -71 | -7 | -156 | -86 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -79 | -77 | -76 | -60 | -83 |
Depreciation & Amortization (Cash Flow) | 3 | 2 | 2 | 3 | 3 |
Income After Depreciation & Amortization | -82 | -79 | -78 | -63 | -86 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 85.60 | 82.64 | 82.16 | 60.75 | 45.27 |
Diluted EPS Before Non-Recurring Items | -1.13 | -0.97 | -0.98 | -1.14 | -2.01 |
Diluted Net EPS (GAAP) | -1.02 | -0.97 | -0.98 | -2.56 | -1.91 |
Fiscal Year end for Ocular Therapeutix, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | NA | 14.77 | 14.80 | 15.08 | 15.19 |
Cost Of Goods | NA | 1.33 | 1.39 | 1.38 | 1.30 |
Gross Profit | NA | 13.45 | 13.42 | 13.70 | 13.88 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 45.07 | 33.47 | 32.92 | 34.45 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -31.62 | -20.05 | -19.22 | -20.57 |
Non-Operating Income | NA | -29.18 | -5.02 | 22.12 | 1.88 |
Interest Expense | NA | 4.05 | 4.15 | 3.43 | 1.99 |
Pretax Income | NA | -64.85 | -29.22 | -0.52 | -20.68 |
Income Taxes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -64.85 | -29.22 | -0.52 | -20.68 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -64.85 | -29.22 | -0.52 | -20.68 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | NA | 132.02 | 90.20 | 85.14 | 78.05 |
Diluted EPS Before Non-Recurring Items | NA | -0.24 | -0.28 | -0.51 | -0.27 |
Diluted Net EPS (GAAP) | NA | -0.49 | -0.12 | -0.25 | -0.26 |